GOLDMAN SACHS GROUP INC - AKERO THERAPEUTICS INC ownership

AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 188 filers reported holding AKERO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of AKERO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$16,746,280
+71.6%
331,085
+58.4%
0.00%
+50.0%
Q2 2023$9,760,218
+14.2%
209,043
-6.4%
0.00%0.0%
Q1 2023$8,543,113
-16.1%
223,291
+20.1%
0.00%0.0%
Q4 2022$10,187,977
-85.9%
185,912
-91.2%
0.00%
-88.2%
Q3 2022$72,145,000
+309.6%
2,118,797
+13.7%
0.02%
+325.0%
Q2 2022$17,612,000
+13.6%
1,863,604
+70.6%
0.00%
+33.3%
Q1 2022$15,505,000
-58.5%
1,092,680
-38.2%
0.00%
-57.1%
Q4 2021$37,366,000
+5261.0%
1,766,714
+5565.5%
0.01%
Q3 2021$697,000
-1.7%
31,184
+9.1%
0.00%
Q2 2021$709,000
-88.3%
28,574
-86.4%
0.00%
-100.0%
Q1 2021$6,076,000
-9.3%
209,427
-19.4%
0.00%0.0%
Q4 2020$6,700,000
+203.2%
259,705
+261.9%
0.00%
+100.0%
Q3 2020$2,210,000
+25.3%
71,758
+1.4%
0.00%0.0%
Q2 2020$1,764,000
+52.2%
70,771
+29.5%
0.00%
Q1 2020$1,159,000
+41.5%
54,663
+48.2%
0.00%
Q4 2019$819,000
+37.9%
36,886
+41.2%
0.00%
Q3 2019$594,000
-46.7%
26,124
-55.1%
0.00%
Q2 2019$1,114,00058,1640.00%
Other shareholders
AKERO THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
ATP Life Science Ventures, L.P. 5,830,203$179,512,00024.20%
venBio Partners LLC 2,444,311$75,260,00011.44%
Versant Venture Management, LLC 777,727$23,946,0004.38%
Redmile Group, LLC 2,336,357$71,936,0001.32%
Vivo Capital, LLC 571,833$17,607,0001.02%
Cormorant Asset Management, LP 859,550$26,466,0001.02%
Boxer Capital, LLC 831,495$25,602,0000.88%
Integral Health Asset Management, LLC 85,000$2,617,0000.80%
EAM Global Investors LLC 49,718$1,531,0000.56%
Crawford Lake Capital Management, LLC 43,826$1,349,0000.56%
View complete list of AKERO THERAPEUTICS INC shareholders